Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

虽然胰 高血糖 素样肽-1受体激动剂（GLP-1 RA）最初开发是用于治疗2型 糖尿病 ，但在研究中，研究人员发现，GLP-1 RA还能够帮助超重和肥胖患者减重，效果十分显著，并且与是否合并糖尿病无关。

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...